AstraZeneca Shares Fall as Investors Question Reported Bristol Myers Merger Talks

AstraZeneca shares dropped sharply on Monday following reports that the British pharmaceutical giant has engaged in merger talks with U.S.-based Bristol Myers Squibb. The potential deal would create one of the world's largest drugmakers with a combined market value of nearly $400 billion, but investors reacted negatively to the news.

Market Reacts with Skepticism

Shares in AstraZeneca fell 6.4% in early London trading, making it the biggest decliner on the FTSE 100 index, according to Reuters. The sell-off reflects significant investor and analyst concern that a transformative acquisition is unnecessary for the company, which has seen strong performance under CEO Pascal Soriot.

Several shareholders voiced their apprehension. "On balance, BMS shareholders would be the winners of any combination with AZN," said Lucy Coutts, investment director at JM Finn, an AstraZeneca shareholder, in comments to Reuters. Markus Manns, a portfolio manager at shareholder Union Investment, stated a combination "does not make strategic or financial sense," warning that "many past mega-mergers have destroyed value."

Strategic Logic Questioned

Analysts questioned the strategic rationale behind such a large-scale merger. Jefferies analysts wrote in a note that they were "puzzled" by the reports, given AstraZeneca's strong "growth and innovation profile." They added, "If there is one company that doesn’t need financial engineering, it’s AstraZeneca."

Ad

While a merger could accelerate AstraZeneca's U.S. expansion and help address a patent cliff expected after 2030, it also presents significant risks. Analysts highlighted potential antitrust scrutiny, particularly given the overlap between Bristol Myers’ cancer immunotherapy drug Opdivo and AstraZeneca’s Imfinzi. Others noted a deal could be "growth-dilutive" for AstraZeneca in the near term and disrupt a well-functioning research and development pipeline.

The Potential Deal by the Numbers

The Financial Times first reported the talks, which a person familiar with the matter later confirmed to Reuters. The key figures based on Friday's market close include:

• Combined Market Capitalization: Nearly $400 billion
• AstraZeneca Valuation: $264.11 billion
• Bristol Myers Squibb Valuation: $133.41 billion
• Potential Market Position: The merged entity would become the world's largest drugmaker by revenue and fourth-largest by market capitalization.

An AstraZeneca spokesperson declined to comment on the reports. Bristol Myers Squibb did not respond to a request for comment, according to Reuters.